|
Strategy and agent | Antagonism against |
|
TF suppression | |
HMGCR inhibitors | Inflammation; thrombosis; miscarriage; APS; cancer growth |
COX inhibitors | Inflammation, APS; thrombosis; miscarriage; cancers |
Vitamin D3 | APS; thrombosis; cancer |
Amiodarone | AT; arrhythmia |
Ethyl pyruvate | Inflammation; coagulation |
NO | Platelet activation; thrombosis |
Indobufen | AT |
Hydroxyurea | Thrombosis |
RNAi | Metastasis |
DMSO | ACS |
Adiponectin | Atherogenesis; diabetes; ACS |
Hairpin ribozym | Thrombosis; I/R injury |
TF sh RNA | Breast cancer growth/angiogenesis |
Metformin | Diabetes II |
Liver X receptor agonists | AT |
Paclitoxel | Cancers |
Antisense TF ODN | I/R injury |
ACE inhibitors | MI |
Nicotinamide | Sepsis; DIC; coagulation; inflammation |
PPARα activation | Obesity; diabetes |
Guggulsterone | Inflammation; AT |
ATRA | Leukemia; CHD |
Phenolics/resveratrol | CHD |
|
FVIIa inhibition | |
BcX-3607 | Thrombosis; inflammation |
FVIIai | Colorectal metastasis; inflammation; thrombosis/MI |
rNAPc2 | Coagulation; inflammation; angiogenesis; tumor growth |
Hemextin AB | Coagulation |
BMS593214 | AT; VT |
PN7051 | Thrombosis |
PHA-798 | Thrombosis |
FFR-rFVIIa | Inflammation; thrombosis; metastasis |
|
FXa inhibition | |
Fondaparinux | DVT; VTE; PE |
Enoxaparin | Inflammation; AT; VT |
WX-FX4 | Metastasis/tumor growth/angiogenesis |
DX-9065a | Inflammation; platelet aggregation; DIC; tumor proliferation |
TAK-442 | Coagulation; VT |
ZK-807834 | Inflammation; AT; VT |
Oral rivaroxaban | AF; VTE |
Oral GW 813893 | Thrombosis |
Oral BMB344577 | Cancer proliferation |
Oral apixaban | Platelet aggregation |
LMWH AVE5026 | AT; VT; coagulation |
Oral DU176b | Thromboembolism; coagulation |
Oral sulfanilamide | Coagulation |
Oral DPC423 | Thrombosis |
Oral YM-75466 | Thrombosis |
MCM09 | Cancer metastasis |
Oral BAY597939 | Thromboembolism |
Ixolaris | Tumor growth; angiogenesis |
NAP5 | Coagulation |
Tinzaparin | Metastasis |
SamOrg123781A | AT |
rTAP (rAST) | Thrombosis; restenosis |
Rivaroxaban | Stroke; AF |
|
FIIa inhibition | |
FM-19 | Platelet activation; ACS; tumor growth |
Dabigatran etexilate | Breast cancer progression |
Argatroban | DVT; VTE; tumor migration/metastasis |
Heparin | Inflammation; DVT; VTE; pregnancy loss; metastasis |
Foypan | Metastasis |
Ximelagatran | DVT; VTE; AT |
Hirudins | Inflammation; DVT; VTE; AT |
Org 42675 | AT |
|
PAR blockade | |
SCH 7979 | Inflammation; platelet aggregation; I/R injury; cancer cell motility/metastasis/angiogenesis |
RWJ 56110 | Platelet aggregation; thrombosis |
RWJ 58259 | Platelet aggregation; vascular occlusion; neointimal thickness; restenosis; thrombosis |
PAR-1 antibody | Platelet aggregation |
PAR-2 mAb | Joint inflammation |
ENMD-1068 | Joint inflammation |
P4pal | DIC; thrombocytopenia; I/R injury |
YD-3 | Platelet aggregation |
SFLLR | Platelet aggregation |
FR 171113 | Platelet aggregation; AT |
TH146 | Platelet aggregation; thrombosis |
FSLLRY-NH2 | Inflammation |
|
Miscellaneous | |
TFPI | Inflammation; pulmonary fibrosis; VT; pneumonia; RA; cancer; apoptosis |
APC | Inflammation; AT; VT; sepsis; metastasis; apoptosis |
AT-III | Inflammation; thrombosis; metastasis; angiogenesis |
Dilazep | Platelet aggregation; APS |
CNTO 859 | Tumor initiation/growth/angiogenesis |
Anti-TF mAb | Septic shock; DVT; AT/VT; miscarriage |
Oral warfarin | Inflammation; thrombosis; metastasis; tumor growth |
n-3 FA | Inflammation |
|